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Since the advent of the new proteomics era more than a decade ago, large-scale studies of protein profiling have
been used to identify distinctive molecular signatures in a wide array of biological systems, spanning areas of basic
biological research, clinical diagnostics, and biomarker discovery directed toward therapeutic applications. Recent
advances in protein separation and identification techniques have significantly improved proteomic approaches,
leading to enhancement of the depth and breadth of proteome coverage.
Proteomic signatures, specific for multiple diseases, including cancer and pre-invasive lesions, are emerging. This
article combines, in a simple manner, relevant proteomic and OMICS clues used in the discovery and development
of diagnostic and prognostic biomarkers that are applicable to all clinical fields, thus helping to improve
applications of clinical proteomic strategies for translational medicine research.Introduction
A. The post-genome era - advances in clinical proteomic
research
Improved biomarkers are of vital importance for cancer
detection, diagnosis and prognosis. While significant
advances in understanding the molecular basis of disease
are underway in genomics, proteomics will ultimately
delineate the functional units of a cell: proteins and their
intricate interactive networks and signalling pathways in
health and disease.
Much progress has been made to characterize thou-
sands of proteins qualitatively and quantitatively in com-
plex biological systems by the use of multi-dimensional
sample fractionation strategies, mass spectrometry (MS)
and protein micro-arrays. Comparative/quantitative ana-
lysis of high-quality clinical biospecimens (e.g., tissue
and biofluids) of the human cancer proteome landscape
can potentially reveal protein/peptide biomarkers
responsible for this disease by means of their altered
levels of expression, post-translational modifications
(PTMs), as well as different forms of protein variants.
Despite technological advances in proteomics, major
hurdles still exist at every step of the biomarker develop-
ment pipeline [1-12].* Correspondence: elena.lopez.villar@gmail.com; mlatterich@prism-sd.org
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reproduction in any medium, provided the orIn the post-genome era, the field of proteomics has
incited great interest in the pursuit of protein/peptide
biomarker discovery especially since MS has been shown
to be capable of characterizing a large number of pro-
teins and their PTMs
In complex biological systems, in some instances even
quantitatively. Technological advances such as protein/
antibody chips, depletion of multiple high abundance
proteins by affinity columns, and affinity enrichment of
targeted protein analytes as well as multidimensional
chromatographic fractionation, have all expanded the
dynamic range of detection for low abundance proteins
by several orders of magnitude in serum or plasma,
making it possible to detect the more abundant disease-
relevant proteins in these complex biological matrices
[13-21]. However, plasma and cell-extract based discov-
ery research studies aimed at identifying low abundance
proteins (e.g. some kinases) are extremely difficult.
Therefore, it is necessary to develop significant techno-
logical improvements related to identifying this low
abundance, although high biological impact molecules.
Moreover, if these protein kinases to be studied contain
PTMs, it is important to know that spatial and temporal
factors can decrease the efficiency of our study
(e.g. many kinases are regulated by phosphorylation of
the activation loop, which then directly reflects cellular
kinase activity).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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several areas of science, ranging from deciphering mo-
lecular pathogenesis of diseases, the characterization of
novel drug targets, to the discovery of potential diagnos-
tic and prognostic biomarkers, where technology is cap-
able of identifying and quantifying proteins associated
with a particular disease by means of their altered levels
of expression [22-24] and/or PTMs [25-27] between the
control and disease states (e.g.., biomarker candidates).
This type of comparative (semi-quantitative) analysis
enables correlations to be drawn between the range of
proteins, their variations and modifications produced by
a cell, tissue and biofluids and the initiation, progres-
sion, therapeutic monitoring or remission of a disease
state.
PTMs including phosphorylation, glycosylation, acetyl-
ation and oxidation, in particular, have been of great
interest in this field as they have been demonstrated to
being linked to disease pathology and are useful targets
for therapeutics.
In addition to MS-based large-scale protein and pep-
tide sequencing, other innovative approaches including
self-assembling protein microarrays [28] and bead-based
flow cytometry [29] to identify and quantify proteins and
protein- protein interaction in a high throughput man-
ner have furthered our understanding of the molecular
mechanisms involved in diseases.
In summary, clinical proteomics has come a long way
in the past decade in terms of technology/platform
development and protein chemistry, to identify molecu-
lar signatures of diseases based on protein pathways and
signalling cascades. Hence, there is great promise for
disease diagnosis, prognosis, and prediction of thera-
peutic outcome on an individualized basis.
B. Proteomic hindrances for discovery of true candidate
biomarkers
Why is there such a disconnection between biomarker
discovery using modern proteomic technologies and bio-
marker qualification requiring much more stringent ana-
lytical and clinical criteria? Several major obstacles have
been suggested as being responsible for this discrepancy,
including:
(a) technological variability within/across proteomic
platforms;
(b) suitable/unsuitable biospecimen collection, handling,
storage and processing;
(c) capacity/incapacity of credentialing biomarker
candidates prior to costly and time-consuming
clinical qualification studies using well-established
methodologies;
(d) necessity for knowledge in the evaluation criteria
required for these distinct processes in the pipelineand in regulatory science by the research
community;
(e) insufficient publicly available high-quality reagents
and data sets to the cancer research community;
(f ) need for improved data analysis tools for the
analysis, characterization, and comparison of large
datasets and multi-dimensional data;
(g) necessity for proper experimental study design when
performing studies involving clinical samples in
biomarker studies.
If proteomics is to be successfully introduced into clin-
ical diagnostics, universally accepted metrics will be
necessary at many steps along the way, to ensure that
changes observed are attributable to biological states,
not workflow variability. In addition, with the combin-
ation of different OMICS- technologies, more reliable
data can be achieved. A high number of OMICS-
combination-approaches are available for clinical
research. It is always necessary to test different tools in
order to raise a greater level of efficiency for your clin-
ical study [30]. Figure 1 illustrates the proteomic hin-
drances for discovery of true (as opposed to surrogate)
candidate biomarkers.
With regards to discovery, semi-quantitative prote-
omic methodologies routinely used for biomarker
research between normal and diseased states are differ-
ential two-dimensional gel electrophoresis (2DGE), com-
parative label-free and labelling approaches [e.g., 18O
labelling, Isotope Coded Affinity Tags, Isobaric Tag for
Relative and Absolute Quantitation (iTRAQ), Stable Iso-
tope Labelling with Amino Acids in Cell Culture
(SILAC), Absolute Quantitation (AQUA), Multiple Reac-
tion Monitoring (MRM)] followed by liquid chromatog-
raphy mass spectrometry (LC-MS). Although such
comparative analysis yields important information on
possible changes as a result of disease, these current
methods in clinical proteomics based, for the most part,
on MS and its combination with 2DGE, chromatography
or biobead technology, might have limitations related to
the sensitivity concentration level.
Sample preparation
When using the previously mentioned proteomic tools,
sample preparation is one of the most crucial processes
in proteomic analysis and biomarker discovery in solu-
bilized samples. Chromatographic or electrophoretic
proteomic technologies are also available for separation
of cellular protein components. There are, however, con-
siderable limitations in currently available proteomic
technologies as none of these allows for the analysis of
the entire proteome in a simple step because of the large
number of peptides, and because of the wide concentra-
tion dynamic range of the proteome in clinical blood
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Figure 1 Proteomic hindrances for discovery of true candidate biomarkers. This figure illustrates, in a simple manner, relevant discovery
aspects of true candidate biomarkers. Points to be considered are: (a) technological and biological variability within/across proteomic platforms;
(b) suitable/unsuitable biospecimen collection, handling, storage and processing; (c) capacity/incapacity of credentialing biomarker candidates
prior to costly and time-consuming clinical qualification studies using well-established methodologies; (d) the necessity for knowledge in the
evaluation criteria required for these distinct processes in the pipeline and in regulatory science by the research community; (e) insufficient
publicly available high-quality reagents and data sets to the cancer research community; (f) need for improved data analysis tools for the analysis,
characterization, and comparison of large datasets and multi-dimensional data; and (g) necessity for proper experimental study design when
performing studies involving clinical samples in biomarker studies. This implies a network-connectivity in relation to: (h) ensuring the choice of
the correct strategy, (i) conclusion of the clinical proteomic research study when reaching a reprensative number of patients in order to achieve
reliable data, (j) to always carry out inter- and intra-assays of your sample-preparations in order to reproduce your data, (k) to combine different
OMIC-Tools to complement and verify the efficiency of your results, (l) Collaboration between clinicians and expert OMIC-scientists is necessary
for succeess.
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depend on the condition of the starting material. There-
fore, proper experimental design and pertinent sample
preparation are essential for obtaining meaningful results,
particularly in comparative clinical proteomics in which
one is looking for minor differences between experimental
(diseased) and control (non-diseased) samples [31].
Homogenization is one of the preparative steps employed
for preparation of biological samples for proteomic analysis,
and includes processes such as mixing, stirring, dispersing,
or emulsifying in order to change the sample’s physical, but
not chemical properties. Homogenization for proteomics
incorporates five main categories: mechanical, ultrasonic,
pressure, freeze-thaw, and osmotic/detergent lyses. Mech-
anical homogenization for tissues and cells can be accom-
plished by devices such as rotor–stator, and open blade
mills (e.g., Warring blender and Polytron), or pressure
cycling technology (PCT) such as French presses. Rotor–
stator homogenizers can homogenize samples in volumesfrom 0.01 mL to l20 L depending on the tip and motor
used.
For optimum results, the tissue should be cut into
slices, the size of which is slightly smaller than the diam-
eter of the applied stator, as larger samples may clog the
generator’s inlet, making it impossible to achieve effective
homogenization. Depending on the chemical resistance of
a cutting tool, it is possible to homogenize samples under
acidic or basic conditions in order to prevent degradation
by endogenous enzymes. Heat transfer to the processed
mixture is low to moderate and the process usually
requires external cooling. Sample loss is minimal com-
pared to PCT, where by means of a pressure-generating
instrument (Pressure Bioscience, West Bridgewater, MA)
alternating cycles of high and low pressure are applied to
induce cell lysis [32,33].
In relation to protein solubilisation, proteins in bio-
logical samples are generally found in their native state
associated with other proteins and often integrated as a
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lated, proteins in their native state are often insoluble.
Breaking interactions involved in protein aggregation
(e.g., disulfide hydrogen bonds, van der Waals forces,
ionic and hydrophobic interactions) enables disruption
of proteins into a solution of individual polypeptides,
thereby promoting their solubilisation. However, because
of the great heterogeneity of proteins and sample-source
related interfering contaminants in biological extracts,
simultaneous solubilisation of all proteins remains a
challenge. Integration of proteins into membranes, and
their association and complex formation with other pro-
teins and/or nucleic acids hamper the process signifi-
cantly. No single solubilisation approach is suitable for
every purpose, and each sample and condition requi-
res unique treatment. Sample solubilization can be
improved by agitation or ultrasonification, but an
increase in temperature should be avoided. The selection
of the appropriate solubilisation protocol and buffers has
specially been facilitated by the availability of commer-
cial kits, although it is somewhat more expensive than
routine reagent methods [34,35].
To avoid protein modifications, aggregation, or pre-
cipitation resulting in the occurrence of artifacts and
subsequent protein loss, sample solubilization process
requires the use, in the sample buffer of: (1) chaotropes
(urea, thiourea, charged guanidine hydrochloride,-for
e.g.-) that disrupt hydrogen bonds and hydrophilic inter-
actions enabling proteins to unfold with ionizable groups
exposed to solution; (2) ionic, non-ionic and zwitterionic
detergents (SDS, CHAPS, or Triton X-100); (3) reducing
agents that disrupt bonds between cysteine residues
and thus promote the unfolding of proteins (DTT/
dithioerythritol (DTT/DTE) or tributylphosphine (TBP)
or tris-carboxy ethyl phosphine (TCEP)) and (4) protease
inhibitors [36].
Although there is no general procedure to select an
appropriate detergent, nonionic and zwitterionic deter-
gents such as CHAPS and Triton X series are less de-
naturing than ionic detergents, and have been used to
solubilise proteins for functional studies. On the other
hand, ionic detergents are strong solubilizing agents that
lead to protein denaturation. However, sodium cholate
and deoxycholate are soft detergents compatible with
native protein extraction, although variables like buffer
composition, pH, salt concentration, temperature, and
compatibility of the chosen detergent with the analytical
MS procedure, and the way in which to remove it (by
dialysis for example) are all crucial factors that need to
be considered. Usually, tissue disruption and cell lyses
require the combination of detergent and mechanical
methodologies [35]. The proper use of the above
reagents, together with the optimized cell disruption
method, dissolution, and concentration techniquescollectively determines the effectiveness of proteome
solubilization methodologies.
All the previously detailed information, coupled to the
use/study of blood, as a biospecimen in discovery
research (a commonly used biospecimen which is highly
complex and which has a wide dynamic range of protein
concentrations), makes it is very difficult to discover
(measure) low abundance proteins (potential biomar-
kers). One solution to this problem is to develop and
apply nanotechnology in clinical proteomics, as well as
the throughput of analytical measurement systems while
lowering their cost. Not only does nanotechnology have
the potential of fulfilling many criteria required for the
advancement of clinical proteomics, essential changes in
the physicochemical properties of substances on their
conversion to the nanostructured state, but it has also
made it possible to create efficient systems for drug
delivery to targets.
In addition, blood cells offer unique insights into dis-
ease processes. Therefore, erythrocytes, granulocytes,
monocytes, lymphocytes, and platelets are of special
interest for clinical proteomics. Cytometry is currently
widely used as an analytical tool for clinical cell analysis
directly from anticoagulated whole blood and also for
cell sorting to generate pure populations of cells from
heterogeneous and highly integrated mixtures as are
found in the majority of biological environments.
Elispot, slide based cytometry, and tissue arrays together
with high-content screening microscopy are further
upcoming techniques in cytoproteomics. The major
challenge for this type of preanalytical standardization is
related to the use of fresh samples, either for direct mul-
tiparameter analysis of cellular proteomics in whole
blood or body fluids without pre-separation, or for cell
sorting and enrichment strategies for subsequent prote-
omic and functional genomic analysis [37].
C. Nanotechnology to complement clinical proteomics
The identification of unique patterns of protein expres-
sion, or biomarkers, associated with a specific disease is
one of the most promising areas of clinical proteomics.
There is an urgent need to discover new biomarkers that
are useful for early disease diagnosis. Recently, it has
been recognized that the measurement of a panel of
multiple biomarkers has the potential to achieve a much
higher sensitivity and specificity compared with any sin-
gle biomarker in the past. Moreover, the highest inform-
ative content is thought to reside in the low molecular
weight (LMW), low abundance fraction of biological
fluids. Nanotechnology offers new approaches to harvest
low abundant panels of biomarkers. For cancers, if the
disease can be detected prior to the onset of metasta-
ses, this can lead to a significant reduction in cancer
deaths [38].
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(1) to provide access to previously inaccessible data as
related to “-omic” technology components with
unparalleled efficiency and resolution;
(2) to enable innovative therapeutic modalities that
leverage the validated system biology outputs for
exquisitely specific individualized therapy.
Systems biology has the potential for utilizing subtle
biological clues (e.g. “-omic” technology components)
for early detection of disease, predicting patient response
to therapy, and identifying biomarkers to enable effective
targeting of drug- delivery modalities to the disease site.
The field of systems biology is still evolving, however
there is strong evidence in scientific literature support-
ing the promise of nanotechnology as an enabling con-
tributor for extracting the elusive “- omic” data for
clinical analysis.
For example, investigators have recently shown the
ability to reproducibly enhance the presence of the low
molecular weight proteome from serum and plasma
samples to differentiate the stages of disease as well as
predict a patient’s response to therapy. As the utility of
nanotechnology expands to other “-omic” technologies,
the ability to compare and integrate multiple panels of
data subsets will tremendously strengthen the validation
process for biomarker identification. Furthermore, nano-
technology has already demonstrated a clinical impact
upon drug-delivery strategies for a variety of ailments,
particularly cancer indications.
The inherent scale of nanotechnology enables a library
combining surface modifications (e.g. targeting moieties,
charge modifications, stealth) of nanoparticulates, as well
as control over size, shape, and other particle characteris-
tics pending on particle material. This variety of options
allows the rational design of personalized therapies that are
predicated upon established biomarker evidence through
system biology discovery, image analysis, mathematical
modeling and access to effective chemotherapeutics and
other agents [39]. The development of nanotechnology
presents an unprecedented opportunity for point-of-care
testing devices by enabling both greater analyt ical sensi-
tivity and the ability to multiplex protein and nucleic acid
marker evaluations in the same assay [40]. It is certain that
nanotechnology has yet to impart an enabling contribu-
tion towards the overall movement to individualized medi-
cine; thus, the potential of nanomedicine coupled to
clinical proteomics remains undeniable.
Currently, one of the most promising nanotechnological
proteomics under development for medical research is
biosensor-based nanodiagnostics. An example of this is
the development of a magneto-nano sensor protein chip
and a multiplex magnetic sorter based on magneticnanoparticles that allow rapid conversion of discrete bio-
molecule binding events into electrical signals, which can
detect target molecules down to the single molecule level
in less than an hour [41,42]. In consequence, nanotechnol-
ogy in clinical proteomics today, implies a new medical
research direction, dealing with the creation and application
of nanodevices for carrying out proteomic analyses in the
clinic. Nanotechnological progress in the field of atomic
force microscopy facilitates clinical studies on the revela-
tion, visualization and identification of protein disease mar-
kers, in particular of those with sensitivity of 10–17 M,
much greater than the sensitivity of commonly adopted
clinical methods. Also, at the same time, implementation of
nanotechnological approaches into diagnostics permits the
creation of new diagnostic systems based on the optical,
electro-optical, electromechanical and electrochemical
nanosensoric elements at high operating speed [42].
In summary, nanobiotechnology is a new focus in
technological science. It plays a key role in the creation
of nanodevices for the analysis of living systems on a
molecular level. Moreover, nanomedicine allows for
improved understanding of human life while using the
knowledge on human organism at a molecular level. The
use of nanotechnological approaches and nanomaterials
opens new prospects for the creation of drugs and sys-
tems for their directed transport. Implementation of
optico-biosensoric, atomic-force, nanowire and nanopor-
ous approaches into genomics and proteomics will sig-
nificantly enhance the sensitivity and accuracy of
diagnostics and will shorten the time for diagnostic pro-
cedures, thus undoubtedly improving the efficiency of
medical treatment.
D. Bioinformatics : Useful for clinical proteomics
Computational biology covers a wide spectrum of tech-
niques devoted to the generation and use of useful infor-
mation from structure, sequence or relationships among
biological analytes (DNA, RNA, proteins, macromolecu-
lar complexes, etc.). Those methods most useful in clin-
ical studies, including biomarkers research, are chiefly
the following:
– Next Generation Sequencing (NGS) is recently
being used in a detailed study of genes involved in
ColoRectal Cancer (CRC).The authors demonstrated
that sequencing of whole tumour exomes allowed
prediction of the microsatellite status of CGC, and
also, facilitating the putative discovery of relevant
mutations. Additionally, NGS is applicable to
formalin-fixed and paraffin embedded material,
allowing the renewed study of relevant clinic
material in the pathology departments [43,44].
– Once modified residues have been found in
sequencing or proteomic studies, routine sequence-
Lopez et al. Proteome Science 2012, 10:35 Page 6 of 11
http://www.proteomesci.com/content/10/1/35to-sequence and sequence-to-structure comparisons
(MSA: multiple sequence analysis) allow to obtain
valuable information about the functional
implications related to the mutated residues in the
protein context. Multiple alignments of proteins,
and chiefly those based on the comparison of
experimentally obtained three -dimensional atomic
structures (structural alignments), are a very valuable
source of information related to the evolutionary
strategies. This is then followed by the different
members of a family of proteins to conserve or modify
their functions and structures [45].
The analysis of structural alignments allows the
detection of at least three types of regions or
multiple alignment positions according to
conservation: (a). Conserved positions, usually the
key for function or structure maintenance. (b). Tree-
determinant residues, conserved only in protein
subfamilies and related to family- specific active
sites, substrate binding sites or protein-protein
interaction surfaces. These sites contain essential
information for the design of family-specific
activator or inhibitor drugs [46]. And (c), positions
that correspond to compensatory mutations that
stabilize the mutations in one protein with changes
in the other (Correlated mutations). These sites are
very effective for the detection of protein- protein
interaction contacts [47]. These last ones allow for
the selection of the correct structural arrangement
of two proteins based on the accumulation of signals
in the proximity of interacting surfaces.
– Because of the sequence-to-structure comparison,
and in absence of experimental crystal structures,
the homology modelling methods, (also called
comparative modelling or knowledge-based
modelling), can develop a 3D model from a protein
sequence based on the structures of a crystallized
homologous protein. The method can only be
applied to proteins with a common evolutionary
origin: as only for proteins that are hypothesized to
be homologous, this assertion implies that their
three-dimensional structures are conserved to a
greater extent than their primary structures. In the
event where good homology hypothesis cannot be
seconded, alternative methods can be applied in
order to obtain a putative 3D structure. These
procedures, known as “far-homology modelling” or
“threading” methods, provide structures with lesser
confidence compared to those generated using
homology modelling methods.
– Data on the 3D structure of the active centre of a
protein of interest and/or its natural ligands can be
used as a basis for the design of effective drugs. This
rational drug design is usually performed viamultiple docking experiments in the active centre of
the protein of interest. This requires the use of
advanced software such as Autodock-4 [48].
Algorithms such as Autodock-4 allow the evaluation
of not only the docking to a rigid model of the
active centre, and also a certain mobility and
adaptation of the side chain of enzyme residues to
the ligand shape. Commonly, all the calculated
binding conformations to the target protein
obtained in every docking run are clustered
according to scoring criteria (as “the lowest binding
energy model” or “the lowest energy model
representative of the most-populated cluster”) and
sorted according to their estimated free energy of
binding. These computer strategies are a useful cost-
reducing tool to prospect and model new molecules
with potential inhibiting properties or even
successful future drugs. Lately, the rational drug
design approach has been used for putative cancer
therapies, in particular the pharmacological
reactivation of mutant p53 [49]. This promising
strategy implies the simultaneous use of several ways
for the identification of small molecules that target
mutant p53, including “de novo” design and
screening of chemical libraries.
– To conclude this section, molecular dynamics (MD)
techniques are routinely used to obtain refined
models for protein structure, protein-protein and
protein- ligand interactions. MD is a computational
simulation technique in which atoms within
molecules are allowed to interact for a period of
time according to the principles of physics. In the
case of proteins, the relevant forces taken into
account are the electrostatic interactions (of
attraction or repulsion), Van der Waals interactions,
and the properties of the covalent bond (length,
angle, and dihedral angle). As a rule, simulation
times for macromolecular protein complexes are up
to 20 ns and the number of atoms of the simulated
systems is in the order of up to 250,000, including
solvent molecules. MD tools have been used to
simulate the individual behaviour of small protein or
peptides [50], protein-protein interfaces and ligand-
protein relationship in catalytic macromolecular
complexes with GTPase activity [51,52] or kinases
involved in cell signalling pathways (e.g. Src tyrosine
kinase [53] or the protein kinase B/Akt [54]).
E. Sample biobanking omplementation necessary for clinical
proteomics
A Biobank contains several hundred thousand samples
from a broad range of anatomic sites, diseases and with
diverse ethnic representation. All biospecimens are
obtained using stringent standard operating procedures
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searcher that the materials will meet their scientific needs.
In order to require tissue samples with accompanying
clinical outcome data, it is necessary to maintain a BioR-
eserve repository of frozen and fixed tissues with patient
follow-up data.
Through Biobank and BioReserve repositories, it is,
thus, possible to provide a rapid delivery of human tis-
sue, biofluids and tissue derivatives that best meet the
research requirements. Moreover, during a standard col-
lection protocol for sample biobanking, human tissues
or bodyfluids and clinical data can also be custom col-
lected to meet unique requirements. Each donor site
uses a standardized clinical data form and pathologic
data is classified using codes for anatomic site, morph-
ology and behaviour [55].
As a final check, clinical data management associates
review records for each case to ensure complete and
consistent data. The stringent evaluation and classifica-
tion process ensures that scientists receive clinically rele-
vant data to help them in their research. Each
biospecimen is assessed using uniform quality assurance
tests. The pathologists independently confirm the ana-
tomic site and diagnosis for each tissue procured. In
addition, the lab researchers assess the RNA, DNA, pro-
teins etc. integrity of each tissue received. This informa-
tion is pr ovided to scientists before purchase so they
can accurately select the samples which will best meet
their needs. This reduces the number of failed OMICS
and clinical experiments due to inappropriate or poor
quality samples [56].
Considerations and future needs
A. The conventional biomarker development pipeline
It is necessary to integrate genomics, proteomics, nano-
biotechnology/nanomedicine, bioinformatics and bio
banking-sample methodologies with clinicians. The
mapping of the human genome represents a real mile-
stone in medicine and has led to an explosion in discov-
eries and translative research in life sciences. Indeed,
this important knowledge base has enabled rapid devel-
opment in the areas of diagnostics, gene therapy, new
drug targets discovery, and personalized therapies
[57,58]. The expansion of biological knowledge through
the Human Genome Project (HGP) has also been
accompanied by the de velopment of new high through-
put techniques, providing extensive capabilities for the
analysis of a large number of genes or the whole gen-
ome. The completion of the human genome, however,
has presented a new and even more challenging task for
scientists: the characterization of the human proteome.
Unlike the genome project, there are major challenges in
defining a comprehensive Human Proteome Project
(HPP) due to (a) a potentially very large number ofproteins with PTMs, mutations, splice variants, etc.; (b)
the diversity of technology platforms involved; (c) the
variety of overlapping biological “units” into which the
proteome might be divided for organized conquest; and
(d) sensitivity limitations in detecting proteins present in
low abundances.
The conventional biomarker development pipeline
involves a discovery stage followed by a qualification
stage (commonly known as biomarker validation) on
large cohorts, prior to clinical implementation and
designing complementary OMICs strategies. In com-
mon practice, the discovery stage is performed on a
MS-based platform for global unbiased sampling of the
proteome, while biomarker qualification and clinical im-
plementation generally involve the development of an
antibody-based protocol, such as the commonly used
enzyme linked ELISA assays. Although this process is
potentially capable of delivering clinically important bio-
markers, it is not the most efficient process as the latter
is low-throughput, very costly and time-consuming. In
many cases, affinity reagents for novel protein candi-
dates do not even exist and it is difficult to multiplex
targets without creating significant interferences and
cross-reactivity. These limitations of immunoassays have
called for the development of alternative approaches.
The recent surge in the advance of proteomic technolo-
gies centering on targeted MS and protein microarrays
has provided great opportunities for researchers to use
them as “bridging technologies” for clinical proteomic
and OMICS investigation of disease-relevant changes in
tissues and biofluids.
Some recent studies that combine rigorous study
design with a focused mass spectrometry approach,
promise to streamline the discovery and validation
process [59,60]. These studies deviate from the trad-
itional brute-force discovery efforts, geared to find
minute differences between often complex samples, to
employ pre-selection and MRM-based quantification
strategies. This approach significantly enhances the fide-
lity of detecting significant differences between even
low abundance biomarkers. To put it into the perspec-
tive of the proverbial “needle in a haystack” analogy the
“haystack” has not become smaller; however, the
pre-selection of potential biomarkers of significance has
provided the research community with a “magnet” to
make the quest for finding the needle more efficient.
On the other hand, apart from restructuring the bio-
marker development pipeline, it will now become critical
to introduce regulatory science to the proteomics
together with nanotechnology/nanobiomedicine and bio-
informatic research (OMICS technologies in general)
with clinical chemistry community so that all these tech-
nologies can be translated from the laboratory to the
clinic.
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Clinical laboratories have an important role, and clinical
scientists undoubtedly play an important part in the ana-
lytical validation of diagnostic tests and are thus
required to routinely verify (confirm) previously cleared/
approved tests by the regulatory agency in their facilities.
Post-market analytical validation is routinely performed
by clinical researchers via evaluation tests (strategies,
instruments, positive and negative controls, reagents,
etc.), which complies with regulations, specifications, or
conditions. These tests typically involve precision,
accuracy, linearity and lower limits of detection and
quantification.
On setting up a method for an approved multiplex
protein assay using a patient -specific “score”, clinical
scientists should consider the way in which to perform
studies to validate the score. One approach may involve
running an adequate number of positive and negative
patients to assess the performance of such a “score” in
their diagnosis in comparison with their medical charts
and final clinical diagnosis. Additionally, international
collaboration provides an effective means by which to
educate key clinical laboratory audiences about the need
for and use of common technologies and standards in
proteomic and OMICS workflows and to share know-
ledge and experience on commonly interesting targets,
assays and new technologies.
On the other hand, the reduction universally observed
in test development and research activities represents, in
part, a shift from laboratories making their own reagents
and immunoassays to the purchase of the majority of
them from an in vitro diagnostics company.
This is not an entirely negative development. External
quality assessment and proficiency testing data clearly
demonstrate the benefits of automation, including much
improved precision, and there are benefits of scale in cen-
tralizing test development processes. Nevertheless, and as
we previously mentioned, clinical laboratories should play
an active role in the final evaluation of assays and in the
study of their clinical utility in relation to their patients.Table 1 Tips for the discovery of true candidate biomarkers a
Necessity Suggestion
Clinically clearly understood Direct comparison with
Well-characterized clinical specimens for discovery
the relevant clinical population
Several factors have to b
biomarkers, whether for
of results and ensure ap
Well-validated discovery platform which is robust
and reliable
The use of internal stan
proteomic –mass spectr
Clinical evidence for the true candidate biomarker Take into account: (a) w
disease, (b) which is the
where use of the test w
specific pre-analytical fa
This table illustrates the necessities for the successful transition when discovering t
and utilities.When considering requirements for the successful intro-
duction of new diagnostic tests, it is helpful to review the
general criteria that must be met (see Table 1), focusing on
the roles of both research and specialist laboratories and
the somewhat different requirements of high- throughput
routine laboratories [61-64].
C. Integration of OMIC-scientists experts with clinicians
The ultimate goal for translational medicine is its
capacity to perform assays in various clinical samples at
multiple levels: DNA (genome), RNA (transcriptome)
and protein (proteome) coupled to bioinformatics and
nanotechnology/nanobiomedicine and others, using
the knowledge and technologies resulting from large-
scale projects. This workflow provides a genetic basis
and a good opportunity for the community to
characterize and quantify proteins (reflecting genetic
alterations if detectable) and their alterations and PTMs
in the cell.
It is critical to define the final purpose of a biomarker
or biomarker pattern at the onset of the study and to se-
lect the case and control samples accordingly. This is
followed by the experiment design, starting with the
sampling strategy, sample collection, storage and separ-
ation protocols, choice and validation of the quantitative
profiling platform followed by data processing, statistical
analysis and validation workflows. Biomarker candidates
arising after statistical validation should be submitted for
further validation and, ideally, be connected to the dis-
ease mechanism after their identification. Since most
discovery studies work with a relatively small number of
samples, it is necessary to assess the specificity and sen-
sitivity of a given biomarker-based assay in a larger set
of independent samples, preferably analyzed at another
clinical centre. Targeted analytical methods of higher
throughput than the original discovery method are
needed at this point and LC-tandem mass spectrometry
is gaining acceptance in this field [65,66].
The resulting proteomic evidence will corroborate or
complement the genetic aberrations detected in samples,t clinical laboratories
the existing best practice in the population for which it is intended
e taken into account when collecting specimens for the studies of new
a specific clinical study or for a biobank in order to enable interpretation
propriate matching of patient and health controls
dards for identifying specific components and quality control via
ometry and OMICS strategies is critical.
hich is the association of our candidate-biomarker with the relevant
assessment of clinical utility and impact, (c) which are the circumstances
ould be unjustified and (d) Make a rigorous early investigation of the
ctors which might influence interpretation of the resulting data
rue biomarkers from the research environment (lab) to the clinical applications
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cancer and other diseases in the context of biological
and clinical utility. The integration and interrogation of
the proteomic and genomic data (and OMICS data in
general) will provide potential biomarker candidates,
which will be prioritized for downstream targeted prote-
omic analysis. These biomarker targets will be used to
create multiplex, quantitative assays for verification and
pre-screening to test the relevance of the targets in clin-
ically relevant and unbiased samples. The outcomes
from this approach will provide the community with
verified biomarkers which could be used for clinical
qualification studies; high quality and publicly accessible
datasets; and analytically validated, multiplex, quantita-
tive protein/peptide assays and their associated high
quality reagents for the research and clinical community.
It is also important to state that in order to develop
clinical proteomic and OMICS applications using the
identified proteins (with and without PTMs), collabor-
ation between research scientists, clinicians, diagnostic
companies and industry, and proteomic experts is essen-
tial, particularly in the early phases of the biomarker
development projects. Also, complementing the data
with other OMICS tools is crucial. The proteomics mo-
dalities currently available have the potential to lead to
the development of clinical applications, and the chan-
nelling of the wealth of the information produced to-
wards concrete and specific clinical purposes is urgent
[65-67].
New biomarkers can be taken from research by
experts in OMICS and clinicians into routine practice,
provided there is sound evidence of clinical utility, fund-
ing can be assured, mechanisms are in place to ensure
that the test is done only for those likely to benefit, ana-
lytical procedures are simple and robust, and quality is
verified through internal quality control and efficiency
testing procedures. For these requirements to be met in
a timely manner for a specific biomarker, it is essential
to learn from past mistakes and perhaps to think differ-
ently in the future.
For the future, greatly improved involvement and collab-
oration from all interested parties – including experts in
discovery and assay development, in health policy, in clin-
ical trial units, in the diagnostics industry and in laborator-
ies responsible for providing clinical testing – will almost
certainly lead to earlier identification and implementation
of promising new biomarkers [68-71].
Summary of important clues when applying
clinical OMICS strategies for translational
medicine research
(I) Standardizing sample preparation procedures for
each sample (e.g. blood, plasma/serum, etc.), iscritical for obtaining reliable biomarkers and
building a biomarker pattern, since slight changes
in a given sample preparation could lead to very
different protein profiles.
(II) Clinical Proteomics and Bioinformatics for
Translational Medicine research studies include
steps for improvements that should be made and
well-controlled in: (a) analytical tools and
biobanking-samples, (b) discovery, (c) validation,
(d) clinical application, and (e) post-clinical
application appraisal. It is likely that most, if not
all, of the components that are necessary for
clinical success are either readily available, or
could be allocated with more rigorous research
standards and efforts supported by our scientific
community, clinicians, health agencies including
hospitals, diagnostic companies, and industry.
Enthusiasm for the clinical impact of proteomics
may need to be tempered, at present, until robust
evidence can be obtained, but some clinical
successes will eventually be feasible.
(III) The rapid proliferation of Nanotechnology/
nanobiomedicine and the implementation of
sample-Biobanking are revolutionizing science and
technology. There is marked interest regarding the
use of nanotechnologies in medicine coupled to
clinical proteomics, and to complement OMICS
tools in general. Therefore clear advances are
appearing for the discovery of true candidate
biomarkers.
(IV) However, and as a general rule, it must be taken
into account as a very important conclusion, that
without: (a) the correct study design, (b) the
correct and complementary strategies (c)
implementation of robust analytical methodologies
and (d) the necessity for collaboration among
expert OMICS scientists together with clinicians
and the industry, the efforts, efficiency and
expectations to make true candidate biomarkers a
useful reality in the near future can easily be
hindered.
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